Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Oncology Institute (TOI) EBIT: 2020-2025

Historic EBIT for Oncology Institute (TOI) over the last 6 years, with Q3 2025 value amounting to -$8.1 million.

  • Oncology Institute's EBIT rose 4186.1% to -$8.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$41.1 million, marking a year-over-year increase of 3524.43%. This contributed to the annual value of -$60.1 million for FY2024, which is 2194.29% up from last year.
  • Per Oncology Institute's latest filing, its EBIT stood at -$8.1 million for Q3 2025, which was up 4186.1% from -$11.2 million recorded in Q2 2025.
  • Oncology Institute's EBIT's 5-year high stood at -$1.1 million during Q2 2021, with a 5-year trough of -$40.8 million in Q4 2021.
  • For the 5-year period, Oncology Institute's EBIT averaged around -$15.5 million, with its median value being -$14.9 million (2023).
  • Its EBIT has fluctuated over the past 5 years, first crashed by 154014.34% in 2022, then surged by 4531.9% in 2024.
  • Quarter analysis of 5 years shows Oncology Institute's EBIT stood at -$40.8 million in 2021, then skyrocketed by 38.58% to -$25.1 million in 2022, then soared by 39.04% to -$15.3 million in 2023, then grew by 21.97% to -$11.9 million in 2024, then surged by 32.48% to -$8.1 million in 2025.
  • Its EBIT stands at -$8.1 million for Q3 2025, versus -$11.2 million for Q2 2025 and -$9.9 million for Q1 2025.